原创翻译:龙腾网 http://www.flfloor.com 翻译:科科 转载请注明出处
论坛地址:http://www.flfloor.com/bbs/thread-485650-1-1.html

Big pharma war: India slams US for crusading against cheap generics

Washington’s push for intellectual property rights in the pharma industry is an attack on India’s generic drug trade, New Delhi says as a US government report accuses India of distributing counterfeit drugs worldwide.

美国政府一份报告指责印度在全球范围内销售假药,新德里方面表示,美国政府推动制药行业的知识产权,是对印度仿制药贸易的攻击。

Authorities in New Delhi were appalled as the “Special 301 report” published by the United States Trade Representative (USTR) on Saturday pinpointed India – alongside China – as the leading global sources of counterfeit medicines. The document, which reviews the state of intellectual property protection around the world, also alleges that up to 20 percent of drugs sold on the Indian market are fake and represent a danger to public health and safety.

美国贸易代表办公室上周六发布的《301特别报告》将印度和中国列为全球假冒药品的主要来源国,新德里当局对此感到震惊。这份审查全球知识产权保护状况的文件还声称,印度市场上销售的药品中,多达20%是假冒的,对公众健康和安全构成威胁。



"At a time when medicine prices are soaring, the report undermines the efforts seeking to make medicines more affordable domestically. USTR’s push for more protection and enforcement of IP policies would keep medicine prices high globally and place lifesaving treatments out of reach for longer in developing countries.”

“在药品价格飙升之际,这份报告削弱了让各国人民更能负担得起药品的努力。美国贸易代表办公室推动加强知识产权政策的保护和执行,将使全球药品价格居高不下,使发展中国家更长时间内无法获得挽救生命的治疗。”

India is the largest producer of generic drugs in the world with its exports covering 40 percent of generic demand in the US and 25 percent of all medicine market in the UK. Its pharma market was valued at $33 billion in 2017 and is expected to reach $55 billion by 2020.

印度是世界上最大的仿制药生产国,其出口产品占美国仿制药需求的40%,占英国所有药品市场的25%。2017年,它的制药市场价值330亿美元,预计到2020年将达到550亿美元。